Vladimir Joseph Sykora
Keine laufenden Positionen mehr
Profil
Vladimir Joseph Sykora is the founder of Molplex Ltd.
Prior to founding Molplex Ltd, he worked as a Principal at Cyprotex Ltd.
and Morphochem AG.
He holds a doctorate degree from The University of Newcastle and an undergraduate degree from Central University of Venezuela.
Ehemalige bekannte Positionen von Vladimir Joseph Sykora
| Unternehmen | Position | Ende |
|---|---|---|
| CYPROTEX PLC | Corporate Officer/Principal | - |
Molplex Ltd.
 Molplex Ltd. Pharmaceuticals: MajorHealth Technology Molplex Ltd. develops pharmaceutical drugs and ingredients. It focuses on medicines for cancer, infection, stratified medicine, autoimmune diseases and inflammation. Its Optiplex, a drug optimization platform estimates the outcomes of clinical trials integrated with laboratory operations for synthesis and screening. The company was founded in June 2010 and is headquartered in Macclesfield, the United Kingdom. | Gründer | - |
Morphochem AG
 Morphochem AG Miscellaneous Commercial ServicesCommercial Services Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany. | Corporate Officer/Principal | - |
Ausbildung von Vladimir Joseph Sykora
| The University of Newcastle | Doctorate Degree |
| Central University of Venezuela | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Cyprotex Ltd.
 Cyprotex Ltd. Miscellaneous Commercial ServicesCommercial Services Cyprotex Ltd. provides pharmaceutical research and development services. It offers ADME and pharmacokinetic, Biosciences, in vitro skin and ocular testing, physicochemical profiling, in vitro toxicology, in silico prediction, and endocrine disruption. The company was founded by David Leahy in 1999 and is headquartered in Abingdon, the United Kingdom. | Commercial Services |
Morphochem AG
Morphochem AG Miscellaneous Commercial ServicesCommercial Services Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany. | Commercial Services |
Molplex Ltd.
Molplex Ltd. Pharmaceuticals: MajorHealth Technology Molplex Ltd. develops pharmaceutical drugs and ingredients. It focuses on medicines for cancer, infection, stratified medicine, autoimmune diseases and inflammation. Its Optiplex, a drug optimization platform estimates the outcomes of clinical trials integrated with laboratory operations for synthesis and screening. The company was founded in June 2010 and is headquartered in Macclesfield, the United Kingdom. | Health Technology |
